Amphiregulin mRNA (AREG mRNA)

The provided target "AREG mRNA" refers to the messenger RNA transcript encoded by the AREG gene, which is transcribed to produce amphiregulin, a protein ligand of the epidermal growth factor receptor (EGFR). Amphiregulin is part of the EGF family and is critical for processes such as cell growth, tissue development, immune regulation, and cancer progression. The mRNA itself is not directly a therapeutic target, receptor, enzyme, or protein but serves as an intermediary in gene expression regulation. Therapeutic targeting is usually directed at the amphiregulin protein or the EGFR pathway, not the mRNA transcript itself. Stabilization and regulation of AREG mRNA can influence diseases driven by abnormal EGFR signaling, such as skin cancers, but mRNA as such is not considered a canonical therapeutic target. Clarification: - "AREG mRNA" typically designates the mRNA transcript, not the protein or a canonical therapeutic target. The true therapeutic target is amphiregulin (protein), abbreviated AREG. - Entering "AREG mRNA" reflects an incorrect or non-canonical form for a drug target; mRNAs themselves are rare therapeutic targets unless specifically referred to in an RNA-targeting context (e.g., antisense or siRNA therapeutics). - For structured data sets related to therapeutic targets, refer instead to "Amphiregulin" (AREG). Summary: "AREG mRNA" is not a correct or canonical name for a therapeutic target; the correct form is "Amphiregulin" (AREG), which is a protein and a known ligand of EGFR involved in cancer and other pathologies.

Other names

AR mRNAAREGB mRNACRDGF mRNASDGF mRNA